Choroidal neovascularization (CNV) due to non‐age‐related macular degeneration (AMD) causes: Multimodal imaging and treatment outcome in a retrospective case series

Abstract

AbstractPurpose: To present the management (clinical evaluation, fundus imaging and treatment outcome) of patients with non‐AMD related CNV.Methods: We retrospectively reviewed the medical records of a case series with non‐AMD related CNV patients that were referred to our clinic since January 2021 and treated with intravitreal injections of anti‐VEGF (ranibizumab or aflibercept). The following data were retrieved: demographic data, best‐corrected visual acuity (BCVA) at the initial and final visit, number of injections and side‐effects, fundus fluorescein angiography (FFA), optical coherence tomography (OCT) and OCT‐angiography imaging results.Results: We included nine eyes of nine patients (seven females and two males, median age: 59 years, range 19–72): five myopic, three with idiopathic CNV, one with angioid streaks (AS). Median BCVA at presentation was 0.7 (range 0.1–0.8). FFA revealed a classic CNV in all cases (subfoveal: eight cases, extrafoveal: one case). OCT‐angiography confirmed the presence of an active CNV in six out of nine cases. In OCT, there was minimal fluid (five out of nine cases), subretinal fluid (two cases) or both subretinal and intraretinal fluid (two cases). The median number of injections was three (range 1–14) with no reported adverse events. An improvement in BCVA was documented in all cases after treatment. On the final recorded visit, OCT showed minimal/no fluid in all patients while in OCT‐angiography the CNV showed signs of inactivity in the majority cases.Conclusions: Multimodal imaging is useful in the diagnosis, follow‐up and management of cases with non‐AMD related CNV. Most of them demonstrated minimal signs of exudative disease and required less number of anti‐VEGF injections compared to neovascular AMD cases.